Croma-Pharma announces submission for their botulinum toxin to treat glabellar (frown) lines to the German authority BfArM
On July the 8th, Croma-Pharma GmbH (Croma) has stated that the company submitted the drug file of its botulinum toxin product to the German authority BfArM. The filing of the dossier stands for the next essential step towards Croma’s complete aesthetic portfolio in Europe, which already comprises of a comprehensive HA filler range, threads, PRP and skincare products.
Croma has licensed the product from the Korean toxin producer Hugel Inc. for Europe and established a joint venture company in 2018 with Hugel, Inc., in order to develop and commercialize Croma’s HA filler products together with Hugel’s botulinum toxin product in the US, Canada, Australia and New Zealand.
The filing to BfArM marks the first milestone in Croma’s approach to a European wide regulatory approval.
“We are pleased to announce that our toxin has finally been submitted – since quite some time hence, a European company will launch a botulinum toxin, which makes us both, happy and proud. Combining our present product and service offering with the last “missing link” will definitely boost our business and will have a feelable impact not only on our marketing and sales approach, but for sure also on our corporate culture.”, CEO Andreas Prinz points out in a first statement.
Croma’s botulinum toxin submission in Europe is based on 2 completed randomized, placebo-controlled Phase III pivotal trials (BLESS I and II) that enrolled a total of 917 subjects in Europe and the US. A third confirmatory pivotal trial to support the US submission (BLESS III) is currently ongoing in sites in Europe and the US and has completed its interim analysis after all 355 patients completed their visits for the primary endpoint.
About Croma-Pharma GmbH
Founded in 1976, Croma-Pharma GmbH (Croma) is an Austrian family-owned company that specializes in the industrial production of hyaluronic acid syringes for the fields of medical aesthetics, ophthalmology and orthopaedics. Croma currently runs 12 international sales companies and distributes its products in more than 70 countries. Within its global sales network, Croma focuses with own branded products on minimally invasive aesthetic medicine. Besides a broad range of HA fillers from the own production site, Croma markets PDO lifting threads, a Platelet Rich Plasma (PRP) system and a personalized skincare technology in its core strategic markets.
About Hugel, Inc:
Established in Korea in 2001, Hugel is a global leader in medical aesthetics providing botulinum toxin formulation BOTULAX / LETYBO, HA filler The CHAEUM / DERMALAX, and derma cosmetic WELLAGE / PR4 brands. Dedicated to provide proven, high quality medical aesthetic solutions that satisfy both consumers’ and practitioners’ needs, Hugel is leading Korean market for both botulinum toxin and HA filler products and is distributing its products to over 40 countries. Visit: www.hugel.co.kr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion to Launch Both Antigen and Antibody Testing Kits in the U.S.12.8.2020 03:00:00 EEST | Press release
Celltrion Group (KRX:068270) today announced the launch of two rapid kits for SARS-CoV-2 in the US by the third week of August. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200811005863/en/ SAMPINUTE™ COVID-19 Antigen MIA (left) and DiaTrust™ COVID-19 IgG/IgM Rapid Test (Photo: Business Wire) SAMPINUTETM COVID-19 Antigen MIA is an electrochemical immunoassay test for detection of SARS-CoV-2 antigen from nasopharyngeal swab samples, composed of one time use test cartridges and a portable analyzer developed in collaboration with BBB1. DiaTrustTM COVID-19 IgG/IgM Rapid Test is a one-step in-vitro diagnostic test based on immunochromatographic assay designed for the rapid detection of antibodies of the novel coronavirus in healthcare settings in collaboration with Humasis2. Both SAMPINUTETM COVID-19 Antigen MIA (antigen test) and DiaTrustTM COVID-19 IgG/IgM Rapid Test (antibody test) have shown reliable performance and promisi
Moody’s Acquires Stake in MARC, Strengthening Presence in Key ASEAN Market12.8.2020 02:00:00 EEST | Press release
Moody’s Corporation (NYSE:MCO) announced today that it has acquired a minority stake in Malaysian Rating Corporation Berhad (MARC), a credit rating agency serving the Malaysian domestic bond and sukuk markets. The investment strengthens Moody’s presence in Southeast Asia and across domestic bond markets globally, and advances its position as a leader in Islamic finance. Based in Kuala Lumpur, MARC covers corporates and financial institutions, with key strengths in infrastructure and project finance. In addition to its rating services, MARC provides economic and fixed-income research, credit risk solutions, sustainability-linked offerings and finance-related online training programs. “Malaysia’s robust domestic bond market presents an attractive opportunity for Moody’s, and we are excited to build upon our partnership with MARC and its growing portfolio of ratings and services,” said Wendy Cheong, Managing Director and Head of Moody’s Investors Service Asia Pacific. The investment stren
Parimatch Makes Statement of Intent for Newly Legalised Ukraine Gambling Industry11.8.2020 16:38:00 EEST | Press release
Following the signing of Bill No. 2285-d by President Volodymyr Zelenskyi to legalise the gambling industry in Ukraine, Parimatch, the international betting and technology company, has confirmed it will be bidding for the new operating licences in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200811005562/en/ Parimatch Makes Statement of Intent for Newly Legalised Ukraine Gambling Industry (Graphic: Business Wire) Parimatch was founded in Ukraine in 1994 and was amongst the first bookmakers in the CIS region to transition into a digital betting platform. Today, Parimatch has expanded internationally to become a global betting and technology brand. The company now looks to build on its heritage to become the largest and most innovative operator in its home market. Commenting on today’s signing, Sergey Portnov, CEO of Parimatch said: “I would firstly like to congratulate President Zelenskyi for delivering on his
Andersen Global Enhances Africa Platform With the Addition of Law Firm in Gabon11.8.2020 16:30:00 EEST | Press release
Further strengthening its global platform and adding breadth to its regional footprint in Central Africa, Andersen Global announces its expansion into Gabon through a Collaboration Agreement with Libreville-based Business & Law Consulting (B & Law Consulting). The law firm, founded in 2017, is composed of more than 10 professionals who advise businesses in the areas of contract, corporate, commercial, tax, international trade, employments and general business law. “We are devoted to providing our clients with best-in-class solutions and maintain transparency and independence when handling client matters,” Managing Partner Khadidjatou Boussougou said. “Collaborating with Andersen Global is a great opportunity for us to continue to build our momentum and improve the quality of the services offered to our clients at an international level.” Andersen Global Chairman and Andersen CEO Mark Vorsatz said, “I am impressed with the level of efficiency and enthusiasm that B & Law Consulting demon
Immervision Introduces Wide-Angle Distortion Correction Algorithms with Face and Body Protection for Videos on Smartphones11.8.2020 16:00:00 EEST | Press release
Immervision, the Montreal-based developer and licensor of patented, wide-angle optics and imaging technology, today announced new real-time video distortion correction algorithms making videos the same as we see with our human eyes. The algorithms are available for mobile OEMs to license now from Immervision’s exclusive distribution partner CEVA. The addition of these new algorithms to Immervision’s broad imaging processing software portfolio will enhance the differentiation OEMs can deliver in next-generation phones. In phones, the wider field of view (FOV) creates more apparent distortion. The algorithms from Immervision fix stretched bodies, curved lines, object and face proportions in real-time adjusting to the scene without any postprocessing required - all in one solution. Immervision provides different levels of correction, varied projections and real-time adaptation to the scene and supports OEMs creating a differentiated experience. “Video recording on phones is skyrocketing a
K2View Raises $28 Million to Accelerate Rapid Expansion in the DataOps Market11.8.2020 15:00:00 EEST | Press release
K2View, a leading provider of real-time DataOps solutions, today announced its $28 million funding round, which will accelerate the company’s growth and expansion in the emerging DataOps market. Forestay Capital led the round along with funding from Genesis Partners. It comes on the heels of rapid growth that saw over 75 percent CAGR in revenue, with a strong first half of 2020. This investment will be used to support the company’s go-to-market strategy as it continues its expansion in markets ripe for transformation with DataOps, such as telecom, financial services, healthcare, insurance, logistics and more. “The fastest method to achieve true agility and exceptional customer experience is moving away from 30-plus years of application-driven enterprise into the data-driven enterprise. This is a critical component for digital transformation and a massive opportunity for us,” said Achi Rotem, CEO and co-founder of K2View. “As we look to the next stage of our growth, our vision is to con
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom